Business Context and Reporting Period
This Form 8-K Current Report was filed by ADVENTRX Pharmaceuticals, Inc. on July 22, 2009. The filing addresses a change in the Company's senior management structure regarding its principal financial and accounting officers.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and personnel changes rather than financial performance.
Material Changes
- Appointment: Patrick L. Keran, previously the Company's General Counsel, Secretary, and Vice President, Legal, was appointed as the interim Principal Financial Officer and Principal Accounting Officer, effective immediately.
- Departure: Mark N.K. Bagnall ceased his service as Principal Financial Officer and Principal Accounting Officer. He remains a member of the Board of Directors.
Management Commentary and Risks
The filing provides background on Mr. Keran's qualifications, noting his legal experience at Isis Pharmaceuticals and various law firms specializing in corporate finance and governance. No specific financial risks, contingencies, or forward-looking guidance were disclosed in this document.
Investor Verification Checklist
- Verify the effective date of the interim CFO appointment (July 22, 2009).
- Confirm that Mark N.K. Bagnall retains his seat on the Board of Directors.
- Review subsequent filings for the appointment of a permanent Principal Financial Officer.
- Check for any related disclosures regarding the transition of financial reporting responsibilities.